Novavax Stock Price, News & Analysis (NASDAQ:NVAX)

$1.83 0.10 (5.78 %)
(As of 01/18/2018 02:35 PM ET)
Previous Close$1.73
Today's Range$1.71 - $1.88
52-Week Range$0.73 - $2.14
Volume8.92 million shs
Average Volume18.99 million shs
Market Capitalization$551.96 million
P/E Ratio-2.69
Dividend YieldN/A
Beta2.03

About Novavax (NASDAQ:NVAX)

Novavax logoNovavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:NVAX
CUSIP67000210
Phone+1-240-2682000

Debt

Debt-to-Equity Ratio-4.28%
Current Ratio3.31%
Quick Ratio3.31%

Price-To-Earnings

Trailing P/E Ratio-2.69117647058824
Forward P/E Ratio-2.95
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.35 million
Price / Sales38.53
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-91.50

Profitability

Trailing EPS($0.68)
Net Income$-279,960,000.00
Net Margins-726.35%
Return on EquityN/A
Return on Assets-52.58%

Miscellaneous

Employees355
Outstanding Shares323,230,000

Novavax (NASDAQ:NVAX) Frequently Asked Questions

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $8.35 million for the quarter, compared to analysts' expectations of $6.42 million. The firm's revenue was up 158.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.24) EPS. View Novavax's Earnings History.

Where is Novavax's stock going? Where will Novavax's stock price be in 2018?

8 analysts have issued 1-year target prices for Novavax's shares. Their forecasts range from $1.00 to $12.00. On average, they anticipate Novavax's share price to reach $3.98 in the next year. View Analyst Ratings for Novavax.

What are Wall Street analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:

  • 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (1/16/2018)
  • 2. Cantor Fitzgerald analysts commented, "The NanoFlu vaccine top-line data release we previewed as a potentially important catalyst before YE17 is now expected to occur in February 2018." (12/18/2017)
  • 3. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)

Are investors shorting Novavax?

Novavax saw a increase in short interest in the month of December. As of December 29th, there was short interest totalling 42,858,793 shares, an increase of 1.1% from the December 15th total of 43,348,136 shares. Based on an average daily volume of 8,716,137 shares, the days-to-cover ratio is presently 4.9 days. Approximately 13.9% of the company's shares are short sold.

Who are some of Novavax's key competitors?

Who are Novavax's key executives?

Novavax's management team includes the folowing people:

  • James Francis Young Ph.D., Independent Chairman of the Board (Age 64)
  • Stanley C. Erck, President, Chief Executive Officer, Interim Chief Financial Officer, Director (Age 68)
  • Gregory M. Glenn M.D., President, Research and Development (Age 63)
  • John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary (Age 52)
  • John J. Trizzino, Senior Vice President - Commercial Operations (Age 57)
  • James F. Cummings, Vice President - Clinical Development and Translational Medicine
  • Rajiv I. Modi Ph.D., Director (Age 56)
  • Richard H. Douglas Ph.D., Independent Director (Age 64)
  • Gary C. Evans, Independent Director (Age 59)
  • Michael A. McManus Jr., J.D., Independent Director (Age 74)

Who owns Novavax stock?

Novavax's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.45%) and Creative Planning (0.06%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Who sold Novavax stock? Who is selling Novavax stock?

Novavax's stock was sold by a variety of institutional investors in the last quarter, including Creative Planning. View Insider Buying and Selling for Novavax.

Who bought Novavax stock? Who is buying Novavax stock?

Novavax's stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.

How do I buy Novavax stock?

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novavax's stock price today?

One share of Novavax stock can currently be purchased for approximately $1.73.

How big of a company is Novavax?

Novavax has a market capitalization of $551.96 million and generates $15.35 million in revenue each year. The biopharmaceutical company earns $-279,960,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Novavax employs 355 workers across the globe.

How can I contact Novavax?

Novavax's mailing address is 20 Firstfield Rd, GAITHERSBURG, MD 20878-1760, United States. The biopharmaceutical company can be reached via phone at +1-240-2682000 or via email at [email protected]


MarketBeat Community Rating for Novavax (NVAX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  463
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novavax (NASDAQ:NVAX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.382.292.252.22
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.98$3.27$3.35$5.71
Price Target Upside: 87.79% upside119.24% upside188.79% upside278.06% upside

Novavax (NASDAQ:NVAX) Consensus Price Target History

Price Target History for Novavax (NASDAQ:NVAX)

Novavax (NASDAQ:NVAX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2018B. RileySet Price TargetBuy$10.00HighView Rating Details
1/11/2018Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$2.50LowView Rating Details
1/10/2018S&P Equity ResearchLower Price Target$1.81 -> $1.35HighView Rating Details
12/19/2017CitigroupDowngradeBuy -> Neutral$1.00HighView Rating Details
12/18/2017Cantor FitzgeraldReiterated RatingHold$2.00HighView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingNeutralN/AView Rating Details
7/27/2017Chardan CapitalReiterated RatingNeutral$1.50LowView Rating Details
7/26/2017Piper Jaffray CompaniesReiterated RatingHold$1.50LowView Rating Details
1/18/2017FBR & CoReiterated RatingOutperform$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$2.00 -> $1.50N/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Novavax (NASDAQ:NVAX) Earnings History and Estimates Chart

Earnings by Quarter for Novavax (NASDAQ:NVAX)

Novavax (NASDAQ NVAX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.16)($0.15)$6.42 million$8.35 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.16)($0.16)$6.15 million$6.70 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.18)($0.16)$6.17 million$5.68 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.21)$5.45 million$5.40 millionViewListenView Earnings Details
11/9/2016Q316($0.26)($0.24)$4.02 million$3.20 millionViewListenView Earnings Details
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
11/5/2010Q3 2010($0.09)($0.10)ViewN/AView Earnings Details
8/6/2010Q2 2010($0.10)($0.09)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.13)($0.11)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.04)($0.15)ViewN/AView Earnings Details
11/6/2009Q3 2009($0.09)($0.08)ViewN/AView Earnings Details
8/7/2009Q2 2009($0.11)($0.10)ViewN/AView Earnings Details
5/8/2009Q1 2009($0.12)($0.12)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.13)($0.11)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.14)($0.16)ViewN/AView Earnings Details
8/8/2008Q2 2008($0.14)($0.14)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.12)($0.12)ViewN/AView Earnings Details
3/14/2008Q4 2007($0.13)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Novavax (NASDAQ:NVAX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.16)($0.16)($0.16)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Novavax (NASDAQ:NVAX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Novavax (NASDAQ NVAX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 35.69%
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Novavax (NASDAQ NVAX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2017Stanley C ErckInsiderBuy100,000$1.13$113,000.00228,279View SEC Filing  
8/31/2017James F. YoungDirectorSell175,000$1.06$185,500.00View SEC Filing  
7/31/2017Barclay A. PhillipsCFOBuy2,057$0.89$1,830.73View SEC Filing  
5/12/2017Michael A Mcmanus JrDirectorBuy20,000$0.97$19,400.00277,590View SEC Filing  
5/11/2017Barclay A PhillipsCFOBuy25,000$0.84$21,000.0036,612View SEC Filing  
5/11/2017Michael A Mcmanus JrDirectorBuy10,000$0.84$8,400.00257,590View SEC Filing  
5/11/2017Stanley C ErckInsiderBuy50,000$0.84$42,000.00128,279View SEC Filing  
1/31/2017Barclay A. PhillipsCFOBuy1,633$1.12$1,828.96View SEC Filing  
1/31/2017John A. Herrmann IIISVPBuy4,960$1.12$5,555.20View SEC Filing  
12/7/2016Gregory M GlennInsiderBuy1,000$1.45$1,450.004,427View SEC Filing  
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.0085,564View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.003,427View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00247,590View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00200,000View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00321,979View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00357,111View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82301,066View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.8040View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00340,977View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.369,152View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.001,158View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.0014,868View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00250,000View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.0084,868View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.729,868View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.7274,868View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.6480,416View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novavax (NASDAQ NVAX) News Headlines

Source:
DateHeadline
Novavax (NVAX) Downgraded by Zacks Investment Research to SellNovavax (NVAX) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - January 16 at 10:34 AM
Brokers Issue Forecasts for Novavax, Inc.s Q3 2018 Earnings (NVAX)Brokers Issue Forecasts for Novavax, Inc.'s Q3 2018 Earnings (NVAX)
www.americanbankingnews.com - January 15 at 7:40 AM
 Analysts Anticipate Novavax, Inc. (NVAX) Will Announce Quarterly Sales of $8.32 Million Analysts Anticipate Novavax, Inc. (NVAX) Will Announce Quarterly Sales of $8.32 Million
www.americanbankingnews.com - January 14 at 10:34 AM
Novavax (NVAX) PT Set at $10.00 by B. RileyNovavax (NVAX) PT Set at $10.00 by B. Riley
www.americanbankingnews.com - January 11 at 6:18 PM
Why Eastman Kodak, Novavax, and Alamos Gold Slumped TodayWhy Eastman Kodak, Novavax, and Alamos Gold Slumped Today
finance.yahoo.com - January 11 at 4:40 PM
Novavax (NVAX) Price Target Increased to $2.50 by Analysts at Ladenburg Thalmann Financial ServicesNovavax (NVAX) Price Target Increased to $2.50 by Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - January 11 at 3:32 PM
Earnings Visibility Hamper Novavax (NVAX) RatingEarnings Visibility Hamper Novavax (NVAX) Rating
investorplace.com - January 11 at 1:17 PM
ICYMI: Epizyme, MoviePass, And A Bull Call On NovavaxICYMI: Epizyme, MoviePass, And A Bull Call On Novavax
feeds.benzinga.com - January 10 at 7:00 PM
Novavax (NVAX) Given New $1.35 Price Target at S&P Equity ResearchNovavax (NVAX) Given New $1.35 Price Target at S&P Equity Research
www.americanbankingnews.com - January 10 at 5:26 PM
Novavax Analyst Turns Uber-Bullish, Raises Price Target To $10Novavax Analyst Turns Uber-Bullish, Raises Price Target To $10
finance.yahoo.com - January 10 at 4:32 PM
Here's Why Novavax, Inc. Stock Shot Up TodayHere's Why Novavax, Inc. Stock Shot Up Today
finance.yahoo.com - January 10 at 4:32 PM
Novavax terminates Gaithersburg leaseNovavax terminates Gaithersburg lease
finance.yahoo.com - January 10 at 4:32 PM
Novavax up 44% on positive expectations from late-stage study of RSV vaccine in newborns via maternal immunizationNovavax up 44% on positive expectations from late-stage study of RSV vaccine in newborns via maternal immunization
seekingalpha.com - January 10 at 1:34 PM
Top 3 Healthcare Penny Stocks for 2018Top 3 Healthcare Penny Stocks for 2018
finance.yahoo.com - January 7 at 9:34 PM
Novavax (NVAX) PT Set at $2.25 by B. RileyNovavax (NVAX) PT Set at $2.25 by B. Riley
www.americanbankingnews.com - January 7 at 6:50 AM
Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : January 1, 2018Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : January 1, 2018
finance.yahoo.com - January 1 at 10:12 AM
Novavax (NVAX) Raised to Buy at BidaskClubNovavax (NVAX) Raised to Buy at BidaskClub
www.americanbankingnews.com - December 30 at 2:08 PM
Novavax, Inc. (NVAX) Short Interest UpdateNovavax, Inc. (NVAX) Short Interest Update
www.americanbankingnews.com - December 30 at 2:00 AM
Novavax, Inc. (NVAX) Expected to Announce Quarterly Sales of $8.15 MillionNovavax, Inc. (NVAX) Expected to Announce Quarterly Sales of $8.15 Million
www.americanbankingnews.com - December 28 at 5:50 AM
Novavax, Inc. (NVAX) Given Consensus Rating of "Hold" by AnalystsNovavax, Inc. (NVAX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 25 at 3:54 PM
Is Novavax, Inc. a Buy? - Motley FoolIs Novavax, Inc. a Buy? - Motley Fool
www.fool.com - December 25 at 12:22 AM
Is Novavax, Inc. a Buy?Is Novavax, Inc. a Buy?
www.fool.com - December 24 at 9:10 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Novavax, Inc. Investors (NVAX) - Business Wire (press release)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Novavax, Inc. Investors (NVAX) - Business Wire (press release)
www.businesswire.com - December 22 at 10:32 AM
Novavax: Punts On NanoFlu, Accelerates RSV - Seeking AlphaNovavax: Punts On NanoFlu, Accelerates RSV - Seeking Alpha
seekingalpha.com - December 22 at 10:32 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Novavax, Inc. Investors (NVAX)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Novavax, Inc. Investors (NVAX)
finance.yahoo.com - December 21 at 4:35 PM
Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : December 20, 2017Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : December 20, 2017
finance.yahoo.com - December 20 at 10:27 AM
Novavax (NVAX) Downgraded by CitigroupNovavax (NVAX) Downgraded by Citigroup
www.americanbankingnews.com - December 19 at 11:02 PM
More Bad News For Novavax: A Citi DowngradeMore Bad News For Novavax: A Citi Downgrade
finance.yahoo.com - December 19 at 4:30 PM
Why McDermott International, Chicago Bridge & Iron, and Novavax Slumped TodayWhy McDermott International, Chicago Bridge & Iron, and Novavax Slumped Today
finance.yahoo.com - December 19 at 4:30 PM
Novavax shares fall on RSV, NanoFlu vaccine updatesNovavax shares fall on RSV, NanoFlu vaccine updates
finance.yahoo.com - December 19 at 4:30 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novavax, Inc. (NVAX)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novavax, Inc. (NVAX)
www.prnewswire.com - December 19 at 3:19 PM
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ VaccineNovavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine
finance.yahoo.com - December 19 at 10:26 AM
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu(TM) VaccineNovavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu(TM) Vaccine
finance.yahoo.com - December 19 at 10:26 AM
Novavax, Inc. (NVAX) Announces Clinical Updates to RSV F Vaccine and NanoFlu Vaccine ProgramsNovavax, Inc. (NVAX) Announces Clinical Updates to RSV F Vaccine and NanoFlu Vaccine Programs
finance.yahoo.com - December 19 at 10:26 AM
Why Novavax Stock Is Tumbling TodayWhy Novavax Stock Is Tumbling Today
finance.yahoo.com - December 19 at 10:26 AM
Cantor Fitzgerald Reiterates "Hold" Rating for Novavax (NVAX)Cantor Fitzgerald Reiterates "Hold" Rating for Novavax (NVAX)
www.americanbankingnews.com - December 19 at 12:38 AM
ETFs with exposure to Novavax, Inc. : December 15, 2017ETFs with exposure to Novavax, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 4:47 PM
Options Traders Expect Huge Moves in Novavax (NVAX) StockOptions Traders Expect Huge Moves in Novavax (NVAX) Stock
finance.yahoo.com - December 13 at 10:46 AM
$8.15 Million in Sales Expected for Novavax, Inc. (NVAX) This Quarter$8.15 Million in Sales Expected for Novavax, Inc. (NVAX) This Quarter
www.americanbankingnews.com - December 11 at 6:46 PM
Novavax, Leveraging a Productive Quarter, Progress in Key Pipeline AreasNovavax, Leveraging a Productive Quarter, Progress in Key Pipeline Areas
finance.yahoo.com - December 8 at 10:23 AM
The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November - Motley FoolThe 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November - Motley Fool
www.fool.com - December 7 at 10:47 AM
Inside Analysts’ Recommendations for Novavax in November 2017Inside Analysts’ Recommendations for Novavax in November 2017
finance.yahoo.com - December 6 at 4:34 PM
An Overview of Novavax’s Influenza and Ebola VaccinesAn Overview of Novavax’s Influenza and Ebola Vaccines
finance.yahoo.com - December 6 at 4:34 PM
Exploring Novavax’s Vaccine Candidates for RSVExploring Novavax’s Vaccine Candidates for RSV
finance.yahoo.com - December 6 at 4:34 PM
The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in NovemberThe 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November
www.fool.com - December 6 at 1:34 PM
BidaskClub Downgrades Novavax (NVAX) to HoldBidaskClub Downgrades Novavax (NVAX) to Hold
www.americanbankingnews.com - December 2 at 12:36 PM
Where Will Novavax, Inc. Be in 5 Years?Where Will Novavax, Inc. Be in 5 Years?
finance.yahoo.com - December 1 at 5:40 PM
Novavax, Inc. (NVAX) Given Average Rating of "Hold" by BrokeragesNovavax, Inc. (NVAX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 8:16 PM
Zacks: Analysts Anticipate Novavax, Inc. (NVAX) Will Announce Quarterly Sales of $8.15 MillionZacks: Analysts Anticipate Novavax, Inc. (NVAX) Will Announce Quarterly Sales of $8.15 Million
www.americanbankingnews.com - November 23 at 8:46 PM
Novavaxs November Jump: The Start Of Something Bigger? - Seeking AlphaNovavax's November Jump: The Start Of Something Bigger? - Seeking Alpha
seekingalpha.com - November 23 at 5:29 PM

SEC Filings

Novavax (NASDAQ:NVAX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novavax (NASDAQ:NVAX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novavax (NASDAQ NVAX) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.